🏢 官网IRCNMDCodex · 实盘不做把握 6/10
北京时间·🕒 发布 19:00:00时区推断·⟳ 抓取 19:03:33·⚡ 决策 07-22 19:06:10 +2m37s·97.0 天前
CONMED宣布AirSeal机器人解决方案获FDA扩展适应症，可用于Intuitive da Vinci 5 Hex Cannula
本次是CONMED官方披露的FDA cleared扩展适应症，方向上利好AirSeal在da Vinci 5机器人手术环境中的适配范围。
📄 原文CNMD↗ 原文
News Release View printer-friendly version « Back CONMED Corporation Announces Expanded Indication for the FDA Cleared…
不做 CONMED Corporation（CNMD.US）
不做：事件方向正面但只是AirSeal兼容适应症扩展，未披露订单、装机、价格或收入增量；相对13.75亿美元年收入和约十亿美元级市值，短线可量化edge不足，且AirSeal近期召回记录和临近财报会削弱追多性价比。
不做 Intuitive Surgical（ISRG.US）
不做：CONMED耗材适配da Vinci 5对Intuitive只是生态兼容背景，非Intuitive自身订单、装机或适应症重大新增，相对其体量不构成市值级短线催化。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
消息传播链
- CONMED官方宣布AirSeal Robotic Solution获扩展适应症，可用于Intuitive da Vinci 5 Hex Cannula。
- Intuitive此前已披露da Vinci 5更多适应症和生态推进，本次CONMED适配属于生态兼容延展，而非全新机器人平台催化。
- FDA数据库显示CONMED AirSeal部分5mm access port产品存在Class II召回，原因为潜在overpressure alerts。
关键理由
- 本次是CONMED官方披露的FDA cleared扩展适应症，方向上利好AirSeal在da Vinci 5机器人手术环境中的适配范围。
- 量级上，CONMED 2025年净销售约13.75亿美元，AirSeal与烟雾排放只是其增长品类之一，本次未披露新增装机、订单、价格或收入分成，短期业绩增量难以量化。
- Intuitive da Vinci 5生态扩展主要验证兼容性，对Intuitive本身市值级增量更小，不构成可交易主标的催化。
主要风险
- AirSeal相关产品在2026年6月有FDA Class II召回记录，虽不直接否定本次扩展适应症，但会压低市场对产品线利好的追价意愿。
- CONMED将于2026-07-29盘后披露业绩，短线股价更可能受财报和指引驱动，而非单一适应症扩展新闻。
反向证据
- 做多前查反向 · 来源 web · 日期 2026-06-17 · 影响 weakens
FDA Class II召回涉及AirSeal 5mm access port，原因是潜在overpressure alerts，削弱对AirSeal新闻的追多质量。
检索:CONMED AirSeal recall FDA 2026 原文 ↗ - 做多前查反向 · 来源 web · 日期 2026-01 · 影响 weakens
公司2026展望为全年收入13.45亿至13.75亿美元，AirSeal增长已在中期增长叙事中体现，本次未给出超预期增量。
检索:CONMED 2026 outlook AirSeal revenue mix 原文 ↗
原文全文
展开原文 · 2,729 字
News Release
View printer-friendly version « Back
CONMED Corporation Announces Expanded Indication for the FDA Cleared AirSeal® Robotic Solution for Use with the Intuitive da Vinci 5 Hex Cannula
Building on the existing indication for Intuitive’s
“We are pleased to secure and announce this expanded indication for use, which was supported by extensive engineering and technical compatibility testing conducted by CONMED in collaboration with Intuitive,” said
About the AirSeal Robotic Solution
The AirSeal® Robotic Solution is an advanced insufflation solution comprised of an AirSeal® Cannula Cap, AirSeal® and Bifurcated Tube Set designed for use within the da Vinci robotic surgical environment. The AirSeal Robotic Solution is functionally equivalent to AirSeal® access ports delivering the same stable pneumoperitoneum, continuous smoke evacuation, and low-pressure insufflation while working entirely through robotic ports.
About CONMED Corporation
CONMED is a medical technology company that provides devices and equipment for surgical procedures. CONMED’s products are used by surgeons and other healthcare professionals in a variety of specialties including orthopedics, general surgery, gynecology, and thoracic surgery. For more information, visit www.conmed.com.
Forward-Looking Statements
This press release contains forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties, which could cause actual results, performance, or trends to differ materially from those expressed in the forward-looking statements herein or in previous disclosures. For example, in addition to general industry and economic conditions, factors that could cause actual results to differ materially from those in the forward-looking statements may include, but are not limited to the risk factors discussed in the Company's Annual Report on Form 10-K for the full year ended December 31, 2025, listed under the heading Forward-Looking Statements in the Company’s most recently filed Form 10-Q and other risks and uncertainties, which may be detailed from time to time in reports filed by CONMED with the SEC. Any and all forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and relate to the Company’s performance on a going-forward basis. The Company believes that all forward-looking statements made by it have a reasonable basis, but there can be no assurance that management’s expectations, beliefs or projections as expressed in the forward-looking statements will actually occur or prove to be correct.
CONMED Corporation
Dalton Henry
Investor Relations Analyst
IR@conmed.com
Source: CONMED Corporation
View printer-friendly version « Back
CONMED Corporation Announces Expanded Indication for the FDA Cleared AirSeal® Robotic Solution for Use with the Intuitive da Vinci 5 Hex Cannula
Building on the existing indication for Intuitive’s
“We are pleased to secure and announce this expanded indication for use, which was supported by extensive engineering and technical compatibility testing conducted by CONMED in collaboration with Intuitive,” said
About the AirSeal Robotic Solution
The AirSeal® Robotic Solution is an advanced insufflation solution comprised of an AirSeal® Cannula Cap, AirSeal® and Bifurcated Tube Set designed for use within the da Vinci robotic surgical environment. The AirSeal Robotic Solution is functionally equivalent to AirSeal® access ports delivering the same stable pneumoperitoneum, continuous smoke evacuation, and low-pressure insufflation while working entirely through robotic ports.
About CONMED Corporation
CONMED is a medical technology company that provides devices and equipment for surgical procedures. CONMED’s products are used by surgeons and other healthcare professionals in a variety of specialties including orthopedics, general surgery, gynecology, and thoracic surgery. For more information, visit www.conmed.com.
Forward-Looking Statements
This press release contains forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties, which could cause actual results, performance, or trends to differ materially from those expressed in the forward-looking statements herein or in previous disclosures. For example, in addition to general industry and economic conditions, factors that could cause actual results to differ materially from those in the forward-looking statements may include, but are not limited to the risk factors discussed in the Company's Annual Report on Form 10-K for the full year ended December 31, 2025, listed under the heading Forward-Looking Statements in the Company’s most recently filed Form 10-Q and other risks and uncertainties, which may be detailed from time to time in reports filed by CONMED with the SEC. Any and all forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and relate to the Company’s performance on a going-forward basis. The Company believes that all forward-looking statements made by it have a reasonable basis, but there can be no assurance that management’s expectations, beliefs or projections as expressed in the forward-looking statements will actually occur or prove to be correct.
CONMED Corporation
Dalton Henry
Investor Relations Analyst
IR@conmed.com
Source: CONMED Corporation
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。